We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ELISA:OMXHEXElisa Oyj Class A Analysis

Data as of 2026-05-22 - not real-time

€41.70

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Elisa’s price is trading above its short‑term moving averages while the MACD shows a bullish crossover and the RSI sits in a neutral zone, indicating mixed short‑term momentum. The PE ratio sits above the industry average, suggesting the stock is priced for strong earnings that may be hard to deliver. Dividend yield is among the highest in the telecom sector, providing a compelling income component. Beta is exceptionally low, reflecting minimal sensitivity to broader market swings, yet volume has been decreasing, hinting at fading buying interest. Operating margins remain healthy, supporting solid cash generation, but revenue has slipped modestly year‑over‑year, limiting growth momentum.
The DCF fair‑value estimate lies well below the current market price, flagging a sizable valuation gap. The payout ratio approaches the upper limit of sustainability, raising questions about dividend durability. Analyst consensus points to limited upside, with price targets only marginally above current levels. Overall, investors face a trade‑off between an attractive dividend and an overvalued price amid modest growth prospects.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near resistance with bullish MACD signal
  • high dividend yield offering income appeal
  • decreasing volume indicating reduced short‑term buying pressure

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • stable operating margins and positive free cash flow
  • valuation gap between market price and DCF fair value
  • modest revenue decline limiting growth

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • significant overvaluation relative to intrinsic value
  • high payout ratio challenging dividend sustainability
  • limited upside potential based on analyst price targets

Key Metrics & Analysis

Financial Health

Revenue Growth-1.30%
Profit Margin15.26%
P/E Ratio19.5
ROE25.17%
ROA8.59%
Debt/Equity115.75
P/B Ratio5.0
Op. Cash Flow€698.5M
Free Cash Flow€352.3M
Industry P/E17.0

Technical Analysis

TrendNeutral
RSI54.6
Support€40.02
Resistance€42.06
MA 20€41.08
MA 50€41.90
MA 200€41.49
MACDBullish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value€19.66
Target Price€42.24
Upside/Downside1.29%
GradeOvervalued
TypeValue
Dividend Yield5.79%

Risk Assessment

Beta0.00
Volatility15.57%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.